Singapore eDevelopment Ltd, through subsidiary Global BioLife Inc., has initiated advanced research on a new universal therapeutic drug platform known as Linebacker, to combat a range of diseases including Alzheimer’s, diabetes and cancer. The research will be led by two-time Nobel Prize nominee, Mr Daryl Thompson.

SeD said Daryl Thompson would leverage expertise in organic and carbohydrate chemistry, and the use of pandemic technology in combating the Ebola virus, in developing the new drug platform. Unlike curing individual diseases with specific drugs, the Linebacker platform seeks a breakthrough option to cure multiple diseases. It can also potentially combat drug-resistant viruses and antibiotic-resistant bacteria.

Mr Thompson will lead the research to be conducted by Global BioLife, in his capacity as Director of Scientific Initiatives. Global BioLife is an 80%-held subsidiary of SeD’s wholly owned subsidiary, Global BioMedical Inc. The remaining stake of Global BioLife is held in equal proportions by Mr Thompson’s GRDG Sciences LLC and ASX-listed Holista CollTech Limited.

Thompson was nominated for a Nobel Prize in 2015 and 2016 for his research in cutting-edge organic and carbohydrate chemistry as well his research in pandemics technology to fight pandemics such as Ebola. He has used his expertise to initiate research regarding universal therapeutics to cure the world’s deadliest diseases. Mr Scott Truesdell, Research Co-ordinator and Special Projects Leader at Global BioLife, will execute the research on the Linebacker platform.

Global BioLife (www.globalbiolife.com) has engaged US-based Charles River Laboratories International, Inc. (www.criver.com), which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Mr Thompson said: “We expect to obtain validating laboratory data from the universal therapeutic drug platform within the first 6 months and are targeting for the platform itself to be completed within 12 months. We have a unique patented technology and are already getting interest from Big Pharma players and venture capitalists. This interest will rise as the validating data becomes available.”

“Global BioLife recognises the need for affordable cures to emerging pandemics and we will leverage the team’s deep expertise to develop this new universal therapeutic drug platform,” said Dr Tang Peihong, Global BioLife’s Director and CEO. Dr Tang has a PhD in chemical engineering and was selected as National Distinguished Expert in China’s Thousand Talents Plan in 2012.

GRDG Sciences LLC is a natural products discovery drug research company formed in Florida, USA, by Mr Thompson, a natural products scientist. GRDG works with multiple global institutions, such as Charles River. Holista CollTech Ltd is a research-driven biotech company that resulted from the merger of Holista Biotech Sdn Bhd and CollTech Australia Ltd, and is dedicated to delivering first-class natural ingredients and wellness products (www.holista.com).